FDA Approves Higher Dose Nusinersen for Spinal Muscular Atrophy

Why It Matters

The higher dose promises greater functional improvement for SMA patients while preserving the established safety profile, potentially setting a new standard of care and extending the commercial life of Spinraza.

Key Takeaways

• FDA greenlights higher-dose Spinraza regimen.
• Loading phase now two injections two weeks apart.
• Maintenance dosing extended to every four months.
• Phase 2/3 DEVOTE trial shows improved motor function.
• Safety profile remains consistent with original dosage.

Pulse Analysis

Spinal muscular atrophy (SMA) has long been a therapeutic frontier, with Biogen’s nusinersen—marketed as Spinraza—earning the first disease‑modifying label in 2016. By targeting SMN2 splicing, the drug raised survival motor neuron protein levels, dramatically altering prognosis for infants and children. Yet, clinicians have observed variability in response, prompting ongoing research into dose optimization to maximize neurological benefit.

The FDA’s recent endorsement of a higher‑dose schedule stems from the DEVOTE phase 2/3 trial, which compared the intensified regimen against the original protocol. Participants receiving the boosted dose exhibited statistically significant gains in motor milestones, such as the Hammersmith Functional Motor Scale, and reduced respiratory complications. Importantly, adverse events remained aligned with the known safety profile—primarily mild respiratory infections—reinforcing confidence that efficacy can be enhanced without compromising tolerability.

From a market perspective, the approval revitalizes Spinraza’s positioning amid emerging gene‑therapy competitors like onasemnogene abeparvovec. By extending the drug’s therapeutic window, Biogen can sustain revenue streams while addressing payer concerns about long‑term value. Moreover, the move underscores a broader industry trend: refining existing biologics to extract additional clinical upside, a strategy likely to influence future regulatory pathways and investment decisions in rare‑disease therapeutics.